Previous 10 | Next 10 |
Channelchek news releases related Channelchek news releases and Channelchek press releases from 06/03/22 12:00:00 on US and Canada Markets.
New Distributor. Avivagen's management recently announced the Company has signed a new distribution agreement with Nong San Viet Co. to support the continued expansion of Avivagen's OxC-beta feed additive. No details were given on the length of the agreement. We believe that this new distribut...
Award. Kratos' OpenSpace Platform has been selected by Intelsat as a key component to unify the operations of its ground and space systems in its next generation network, which will combine the latest in space, ground and cloud technologies to deliver robust, dynamic and flexible services. Thi...
Voyager Digital Ltd. ("Voyager" or the "Company") (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2) today announced the Company's participation in the following investor events in June 2022: Read More >>
Fiscal Q3 results disappoint. The company reported fiscal Q3 revenue of $15.7 million, 8.7% below our forecast of $17.2 million. Adj. EBITDA loss of $7.3 million missed our expectation of a loss of $4.5 million. Updates fiscal full year outlook. The company plans to generate $55 million to $60...
Improving the extraction process. Initial test work supports using the acid bake process at the Wicheeda rare earth element project based on improved rare earth element (REE) extraction and the potential for lower Wicheeda project capital and operating costs. The previous hydrometallurgical fl...
Product Development Platforms Reach Clinical Trial Milestones. A Phase 1 dose escalation trial has begun treating patients with CF-hNIS Vaccinia, a product from Imugene's oncolytic virus platform. The trial will enroll patients with metastatic or advanced solid tumors. The company has also pub...
Seanergy reported solid results in the 2022-1Q. Revenues, net were $29.7m, up 46% from the same period last year and in line with our $30.3m estimate. With voyage expenses running below expectations, operations income of $7.8m was above our $7.1m estimate. Adjusted EBITDA and net income of $16...
Phase 2 Triple Combination Study Data To Be Presented At ASCO. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 Triple Combination trial is sc...
Phase 2 VERSATILE Study Data To Be Presented. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 VERSATILE-002 clinical trial is scheduled for J...
Recorded May 19, 2022. Noble Capital Markets Senior Research Analyst Joe Gomes sits down with Schwazze CEO & Chairman Justin Dye for this exclusive interview. Topics covered include: An update on recent growth in retail and cultivation What makes Colorado & New Mexico such attractive m...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
60.33%Change Percent:
TransCode Therapeutics Inc. Company Name:
RNAZ Stock Symbol:
NASDAQ Market:
transcodetherapeutics.com Website: